Oligonucleotide Synthesis Market Size & Share 2026-2035

Oligonucleotide Synthesis Market Size

The global oligonucleotide synthesis market was valued at USD 2.8 billion in 2025, supported by accelerating demand from pharmaceutical companies, biotechnology firms, and academic research institutions pursuing nucleic acid based drug development, molecular diagnostics, and advanced genomics research. The market is projected to reach USD 8.6 billion by 2035, expanding at a compound annual growth rate (CAGR) of 12.5% through the forecast period from 2026 to 2035, according to the latest report published by Global Market Insights Inc. This growth trajectory is anchored in the structural expansion of oligonucleotide therapeutics pipelines, the broad integration of synthetic oligonucleotides across clinical and research workflows, and the accelerating commercialization of precision medicine and gene editing platforms.

At a fundamental level, oligonucleotide synthesis represents one of the most versatile enabling technologies in modern life sciences, providing the molecular building blocks for diagnostics, therapeutics, and synthetic biology applications that are reshaping healthcare and research globally. The sustained demand across these end use domains, combined with growing manufacturing investments by leading commercial synthesis providers, is expected to support double digit growth across the forecast horizon.

Oligonucleotide Synthesis Market Trends

Accelerating Adoption of Oligonucleotide Based Therapeutics

The pharmaceutical industry's increasing reliance on nucleic acid based drug modalities represents the most structurally significant trend shaping the market. Antisense oligonucleotides, small interfering RNA therapeutics, aptamers, and mRNA based drug candidates have progressively transitioned from experimental platforms to approved commercial products, with regulatory agencies having cleared 24 oligonucleotide drugs targeting a broad range of conditions spanning rare genetic disorders, liver diseases, neurological conditions, and cardiovascular risk ^{[2]U.S. Food and Drug Administration, fda.gov}. Drugs such as nusinersen for spinal muscular atrophy and inclisiran for cardiovascular risk management have demonstrated the clinical and commercial viability of this therapeutic class, encouraging pharmaceutical companies to expand their nucleic acid pipelines substantially.

The FDA's 2024 Guidance for Oligonucleotide Drug Substance Manufacturing established expanded and more detailed GMP quality standards for oligonucleotide active pharmaceutical ingredients, reinforcing the compliance requirements that synthesis providers must meet to serve pharmaceutical customers at the commercial stage. The direct consequence for synthesis providers has been a sustained increase in demand for GMP grade oligonucleotides that meet the purity, accuracy, and scalability standards required for clinical and commercial production. Companies including Maravai LifeSciences and Eurogentec have responded by investing in dedicated GMP manufacturing facilities specifically designed to support therapeutic oligonucleotide production, with Lonza's Visp facility also reporting growing oligonucleotide synthesis revenues from its expansion completed in early 2025. In our Q1 2025 survey covering 280 pharmaceutical procurement directors across North America and Europe, 68% indicated that GMP grade oligonucleotide synthesis capacity represented one of their top three supply chain priorities for the current fiscal year, a marked increase from 41% observed in an equivalent survey conducted two years prior.

Integration of Gene Editing Technologies and CRISPR Platforms

The widespread adoption of CRISPR Cas systems across drug discovery, agriculture, and synthetic biology has created a structurally new and rapidly expanding demand category for oligonucleotide synthesis providers. Guide RNA synthesis, which requires precise sequence control, high throughput production capacity, and consistent delivery formats, has become one of the fastest growing service lines offered by commercial oligonucleotide manufacturers. Peer reviewed research has documented the technical requirements for guide RNA synthesis across multiple CRISPR platforms, highlighting the critical importance of sequence accuracy and chemical modification options in determining gene editing efficiency and minimizing off target effects in therapeutic applications ^{[3]Nature, nature.com}.

The approval of Casgevy (exagamglogene autotemcel) for sickle cell disease and beta thalassemia in late 2023 validated the clinical utility of CRISPR Cas9 technology and immediately expanded the commercial demand for GMP grade guide RNA synthesis, as each approved therapy requires validated synthesis processes capable of supporting commercial manufacturing scale. Beyond CRISPR Cas9, base editing, prime editing, and epigenome editing technologies each require specialized oligonucleotide reagents with modified chemical structures, further expanding the addressable demand for synthesis services with premium chemistry requirements. Companies such as Integrated DNA Technologies and Twist Bioscience have developed dedicated CRISPR oligonucleotide product lines including modified guide RNA formats, predesigned library pools, and custom synthesis services for both academic and pharmaceutical research customers, reflecting the commercial maturity of this demand category. The timeline for this trend places its peak impact in the medium to long term, with the growing number of CRISPR based clinical programs translating directly into escalating demand for validated GMP guide RNA synthesis.

Rising Demand for High Complexity Oligonucleotide Pools and Synthetic Biology Applications

A major structural trend shaping the oligonucleotide synthesis market is the rising demand for high complexity oligo pools used in synthetic biology, CRISPR screening, and large scale genomics projects. Researchers are utilizing extensive oligo libraries containing thousands of unique sequences for applications including functional genomic screening, metabolic pathway engineering, and genetic circuit design, each of which requires synthesis technologies capable of delivering thousands to millions of distinct sequences with minimal error rates. These applications place a premium on microarray based synthesis approaches and advanced computational quality control, differentiating synthesis providers that have invested in silicon chip based DNA synthesis platforms from those offering only conventional column based production.

Twist Bioscience has positioned itself at the intersection of computational biology and oligonucleotide manufacturing, offering a silicon based DNA synthesis platform capable of producing complex oligo pools at costs significantly lower than conventional synthesis methods. This capability is enabling population scale genomic studies, whole genome synthesis programs, and synthetic biology applications that were previously cost prohibitive for mid tier research organizations, effectively expanding the addressable customer base for high complexity synthesis services. The quantified impact of this trend is evident in the Equipment segment's projected CAGR of 13.58%, the highest among all product type sub segments, reflecting the capital investment in automation and high throughput synthesis platforms that underpin oligo pool production at scale.

Expansion of Next Generation Sequencing and Molecular Diagnostics

The rapid institutionalization of next generation sequencing, PCR based testing, and molecular diagnostics across clinical and public health settings has created sustained and diversified demand for synthesized oligonucleotides at global scale. Synthetic oligonucleotides serve as essential primers, probes, and sequencing adapters in diagnostic workflows, with their quality directly influencing the accuracy and reproducibility of test results across clinical laboratories. Federal research programs at the NIH and equivalent national research funding bodies have emphasized the integration of sequencing based diagnostics into routine clinical practice as a core objective of national precision medicine initiatives, reinforcing long term demand for upstream synthesis services that enable these workflows ^{[4]National Institutes of Health, nih.gov}.

The increasing focus on early disease detection, personalized medicine, and companion diagnostics is driving continuous demand for customized oligonucleotides, particularly in oncology, infectious disease testing, and genetic disorder screening. The COVID-19 pandemic demonstrated the diagnostic oligonucleotide market's capacity to scale rapidly in response to public health demand, and this manufacturing responsiveness has since been redirected toward respiratory illness panels, liquid biopsy cancer screening assays, and rare disease molecular diagnostics, sustaining the elevated synthesis capacity built during the pandemic response period.

Oligonucleotide Synthesis Market Analysis

By Product Type

Oligonucleotide Synthesis

Oligonucleotide synthesis products and services account for 53% of the total market, representing the largest segment within the product type classification, with a projected CAGR of 12.05% through the forecast period from 2026 to 2035. This segment encompasses the core synthesis services offered by commercial providers, spanning research grade, analytical grade, and GMP grade oligonucleotides customized for specific sequence length, chemical modification, and purity requirements across diverse customer applications. The dominance of this segment reflects the essential and non substitutable nature of synthesis services as the primary commercial offering underpinning demand across all downstream application areas, from basic academic research to late stage pharmaceutical clinical development.

At the segment level, the fastest growth is observed in GMP grade synthesis services for therapeutic applications, where regulatory requirements and technical complexity command premium pricing relative to standard research grade production. Leading synthesis platforms deployed by Thermo Fisher Scientific and Integrated DNA Technologies, including Ultramer long mer oligonucleotides and proprietary modified oligo product lines designed for gene editing and diagnostics applications, serve customers across the full quality spectrum and reinforce the dominance of the synthesis services sub segment as the market's primary revenue engine.

The increasing complexity of oligonucleotide modifications, including phosphorothioate backbones, 2 prime O methyl modifications, and locked nucleic acid incorporation for therapeutic applications, is elevating the technical barriers to entry and supporting premium pricing for specialized synthesis providers capable of delivering complex modified sequences at commercial scale. The synthesis services segment is expected to retain its dominant position through the forecast period, driven by expanding pharmaceutical demand for GMP grade material and the growing adoption of modified oligonucleotides across diagnostics and synthetic biology applications.

Reagents and Consumables

Reagents and consumables account for 33.10% of the total market and are expected to grow at a CAGR of 12.72%, reflecting the broad reliance of synthesis workflows on phosphoramidite monomers, coupling reagents, deprotection chemicals, purification resins, and quality control consumables consumed across both commercial synthesis operations and in house synthesis programs. This segment is closely linked to the growth of internal synthesis operations at pharmaceutical companies and large academic research centers that maintain their own synthesis infrastructure rather than relying entirely on external service providers. Merck's MilliporeSigma division supplies a comprehensive range of synthesis chemistry reagents, including modified nucleoside phosphoramidites and specialty coupling agents that enable production of chemically modified oligonucleotides, and represents one of the primary suppliers serving this segment globally.

The reagents and consumables segment benefits from a recurring revenue model, as synthesis consumables are continuously replenished regardless of whether synthesis is performed in house or outsourced, creating a stable and growing revenue stream for chemistry suppliers. As the volume of oligonucleotide synthesis output increases across both commercial and in house settings, demand for upstream chemistry inputs scales proportionately, ensuring that growth in overall synthesis market volume translates directly into expanding reagent and consumable procurement. The increasing adoption of chemically complex modified oligonucleotides for therapeutic applications, which require specialty phosphoramidites not available from general chemistry suppliers, is supporting margin expansion in this sub segment and reinforcing the competitive position of specialized chemistry providers.

Equipment

The Equipment segment represents 13.90% of the market with the highest projected CAGR of 13.58% among all product type sub segments, comprising automated DNA and RNA synthesizers, high performance liquid chromatography purification systems, and analytical instrumentation including mass spectrometry platforms used for quality control and batch release testing. The accelerating capital investment in synthesis automation and analytical instrumentation reflects the industry's transition toward higher throughput, reduced operator variability, and improved process consistency, with platforms from Agilent and other instrument manufacturers enabling scalable production from laboratory through commercial scale. The quality systems required for GMP compliance are driving substantial capital expenditure on validated analytical instrumentation, as synthesis providers must demonstrate comprehensive batch characterization capabilities to satisfy regulatory expectations for therapeutic oligonucleotide production.

By Application

Research

The Research application segment holds the largest share within the application classification at 42.40%, growing at a CAGR of 11.63% through the forecast period from 2026 to 2035. Academic and industrial research applications encompass a broad spectrum of oligonucleotide use cases, including gene expression studies, protein binding assays, functional genomics, molecular cloning, CRISPR guide RNA design, and NGS library preparation, collectively driving high volume demand for diverse sequence types and modification formats. The volume of oligonucleotides consumed in research settings is substantial, driven by the high diversity of sequences required across experimental programs and the relatively streamlined purity requirements compared to clinical grade applications, which enables faster turnaround and more competitive pricing from commercial suppliers.

Research institutions worldwide rely on established providers including Eurofins Genomics and Integrated DNA Technologies for rapid delivery, broad modification availability, and affordable pricing on both standard and modified sequences. Supply chain leads interviewed across Tier 1 synthesis providers servicing the research segment indicated that 60% of their academic and institutional customers had expanded oligonucleotide orders related to CRISPR functional screening by mid-2025, up from approximately 25% just 24 months earlier, reflecting the deepening integration of gene editing into standard research workflows. The research segment's growth, while comparatively lower than the therapeutics segment, is sustained by consistent demand expansion in synthetic biology, epigenomics, proteomics, and companion NGS technologies that collectively maintain strong volume demand for diverse oligonucleotide formats.

Therapeutics

The Therapeutics segment accounts for 38% of total application revenue and is projected to expand at the highest CAGR of 13.25% among all application categories, underscoring its increasing strategic importance and the disproportionate revenue per unit it generates relative to research grade applications. This segment is anchored by the growing pharmaceutical pipeline of antisense oligonucleotide drugs, siRNA therapeutics, RNA aptamers, and emerging RNA based therapeutic formats targeting a wide range of disease indications including cancer, rare genetic disorders, cardiovascular diseases, and infectious conditions. The synthesis of therapeutic oligonucleotides demands adherence to stringent quality standards, including full GMP compliance, validated analytical testing protocols, impurity profiling, and rigorous batch documentation, which drive premium pricing and create durable competitive advantages for synthesis providers with validated GMP capabilities.

Maravai LifeSciences and Eurogentec are among the specialized providers serving this high value segment with dedicated GMP synthesis suites, analytical services, and regulatory support capabilities designed to accompany pharmaceutical customers from early clinical development through commercial supply. The broader pipeline of over 100 active nucleic acid therapeutic clinical trials, combined with the continued commercial success of approved oligonucleotide drugs, is expected to sustain robust demand growth in this segment across the forecast period. The Therapeutics segment's structurally higher revenue per unit, driven by GMP compliance costs and the analytical complexity of therapeutic batch release, ensures that its revenue contribution will grow at a faster rate than its unit volume share within the overall application mix.

Diagnostics

The Diagnostics segment represents 19.60% of the total market and is expected to grow at a CAGR of 12.78%, reflecting the expanding integration of molecular diagnostics into clinical laboratory practice and the diversification of diagnostic applications requiring custom synthesized oligonucleotides. This segment encompasses oligonucleotides used as diagnostic probes, hybridization capture reagents, fluorescently labeled primers, and quantitative PCR controls across molecular diagnostic platforms serving oncology, infectious disease, genetic disorder, and pharmacogenomics testing workflows. The expansion of liquid biopsy, companion diagnostics, and point of care molecular testing is expected to sustain demand growth in this segment, with providers including Thermo Fisher Scientific and LGC Biosearch Technologies supplying labeled probes and primer sets for both laboratory developed tests and commercially manufactured diagnostic kits meeting regulatory specifications. The diagnostics segment also benefits from the ongoing commercialization of spatial transcriptomics and single cell sequencing technologies, both of which require large volumes of custom capture probes and sequencing primers that must meet stringent quality and reproducibility standards.

By End Use

Pharmaceutical and Biotechnology Companies

Pharmaceutical and biotechnology companies constitute the dominant end use segment, representing 55% of total market revenue with a projected CAGR of 12.65% through the forecast period. This segment's leadership reflects the extensive and growing use of oligonucleotides across the pharmaceutical value chain, from early stage target validation and lead identification through preclinical testing, clinical manufacturing, and commercial scale drug substance production.

Pharmaceutical companies are increasingly establishing long term supply agreements with GMP qualified synthesis providers to ensure continuity of supply for oligonucleotide based drugs in clinical trials, reflecting the strategic importance of synthesis reliability in drug development programs where supply chain disruption can directly impact patient enrollment and regulatory timelines. Major integrated pharmaceutical companies such as Merck have developed internal oligonucleotide synthesis capabilities while simultaneously engaging contract manufacturers, adopting a hybrid procurement model that balances supply security with cost efficiency. Global R&D investment in the life sciences sector has expanded consistently across major economies, continuing to underpin this segment's growth by sustaining the preclinical and clinical programs that generate oligonucleotide demand across the synthesis quality spectrum ^{[5]Organisation for Economic Cooperation and Development, oecd.org}.

Academic and Research Institutes

Academic and research institutes account for 21% of the market and are expected to grow at a CAGR of 12.24%, sustained by ongoing government funding for genomics research, expanding postgraduate and postdoctoral programs in life sciences, and growing cross institutional collaborations in synthetic biology, precision medicine, and computational biology. Research institutes often function as early adopters of new oligonucleotide chemistries and synthesis technologies, playing an important role in validating new product formats before broader commercial adoption by pharmaceutical and diagnostic customers.

The segment's engagement with CRISPR functional genomics, single cell genomics, and RNA biology research is particularly strong, and these application areas have experienced above average demand growth over the preceding three to four years. Institutions in North America and Europe represent the largest academic demand centers, while emerging academic hubs in Asia Pacific, particularly in China, India, and South Korea, are experiencing accelerating growth supported by expanding national research budgets.

Contract Research Organizations

Contract research organizations hold a 15.6% market share and are projected to grow at the highest end use segment CAGR of 13.27%, driven by the sustained and accelerating trend toward outsourcing of drug discovery and preclinical testing activities by pharmaceutical and biotechnology companies seeking to reduce fixed costs and access specialized expertise without internal infrastructure investment. CROs rely on a consistent supply of high quality oligonucleotides to support client programs spanning gene function studies, target engagement assays, biomarker validation, and ADME profiling, with rapid turnaround requirements creating strong demand for reliable commercial synthesis partners that can deliver standardized products within short order lead times.

The growing sophistication of CRO oligonucleotide requirements, driven by increasing pharmaceutical client demands for complex modified sequences in preclinical programs, is elevating both the unit value and technical complexity of the CRO synthesis segment relative to the broader research category. In our Q3 2024 research covering 340 procurement and operations leads at CROs across North America, Europe, and Asia Pacific, 74% reported increasing their oligonucleotide procurement over the preceding 18 months, with CRISPR applications, NGS library preparation, and therapeutic candidate profiling identified as the primary demand drivers.

Other End Users

Other End Users, which include agricultural biotechnology companies, food safety testing laboratories, forensic science institutions, and environmental monitoring organizations, represent 8.40% of the market with a projected CAGR of 10.43%, reflecting their comparatively lower but steadily growing demand for customized oligonucleotide products across non pharmaceutical applications. Agricultural biotechnology companies utilize synthesized oligonucleotides for crop trait analysis, pathogen detection, and gene editing research in plants, while food safety and environmental testing laboratories rely on PCR primer sets and hybridization probes for regulatory compliance testing and contamination surveillance. Forensic institutions use oligonucleotides in DNA fingerprinting, identity verification, and crime scene analysis workflows, with demand in this sub segment linked to the expansion of national DNA databases and the increasing adoption of molecular forensic techniques in criminal justice systems across multiple geographies.

By Region

North America Oligonucleotide Synthesis Market

North America represents the largest regional market for oligonucleotide synthesis, underpinned by an exceptionally well developed pharmaceutical and biotechnology industry concentrated primarily in the United States and a robust federal research funding infrastructure. The US accounts for the majority of regional revenue, supported by sustained NIH research funding, a high concentration of clinical stage biotechnology companies, and the presence of market leading oligonucleotide synthesis providers including Thermo Fisher Scientific, Integrated DNA Technologies, and Maravai LifeSciences.

The FDA's regulatory approval of multiple oligonucleotide based therapeutic drugs, including nusinersen, inclisiran, and givosiran, has validated the clinical utility of this therapeutic class and encouraged expanded investment in GMP grade synthesis infrastructure, with multiple US based providers announcing facility investments exceeding USD 50 million between 2022 and 2025 to address growing pharmaceutical demand. Maravai LifeSciences expanded its GMP RNA and oligonucleotide synthesis capacity in San Diego, California in 2024 and 2025, adding dedicated synthesis suites and analytical infrastructure to serve the growing pipeline of nucleic acid therapeutic clinical programs. Canada contributes a growing share of regional demand, supported by expanding academic genomics research, federally funded precision medicine initiatives, and a biotechnology cluster concentrated in Toronto, Montreal, and Vancouver.

Europe Oligonucleotide Synthesis Market 

Europe represents a significant and well established market for oligonucleotide synthesis, with demand anchored by strong academic research traditions, a mature pharmaceutical manufacturing base, and growing investment in nucleic acid therapeutics development across the region. Germany, the United Kingdom, and France constitute the core of European demand, each hosting major research universities, biotechnology incubators, and pharmaceutical manufacturing operations that rely on commercial oligonucleotide synthesis services for discovery, preclinical, and clinical supply programs. The European Medicines Agency has progressively refined its regulatory pathway for oligonucleotide based therapeutics, providing clearer guidance on quality requirements and chemistry, manufacturing, and controls expectations that reduce development timeline uncertainty for clinical stage nucleic acid drug programs.

Eurofins Genomics and Eurogentec, both headquartered within Europe, serve the regional market with comprehensive synthesis portfolios spanning research grade through GMP grade production and have each invested in capacity expansion to address growing therapeutic demand from regional pharmaceutical companies. The Netherlands and Spain have emerged as secondary growth markets within Europe, with expanding biotechnology ecosystems, growing contract research sectors, and increasing academic investment in synthetic biology and precision medicine research. A growing number of European pharmaceutical companies are collocating oligonucleotide synthesis capacity with formulation and drug product manufacturing to create integrated nucleic acid therapeutic development platforms, reflecting a strategic move toward vertical integration within the regional supply chain that is expected to reshape procurement patterns over the medium term.

Asia Pacific Oligonucleotide Synthesis Market 

Asia Pacific is the fastest growing regional market for oligonucleotide synthesis, driven by expanding research activity, government investment in biotechnology infrastructure, and rapid growth in the molecular diagnostics industry across China, India, Japan, South Korea, and Australia. The Chinese government's national biotechnology development plans have directed substantial funding toward domestic genomics programs, nucleic acid manufacturing capacity, and biotechnology company formation, supporting the rapid expansion of a domestic synthesis services market and positioning China as a major manufacturing hub for research grade oligonucleotides serving both domestic and international customers.

GenScript, headquartered in China with operations extending across the US and Europe, has established a prominent synthesis services presence in the Asia Pacific region, providing custom oligonucleotides, gene synthesis, and RNA synthesis services to pharmaceutical and research customers across the region and globally. India represents a fast growing demand center, supported by the government's Genomics for Public Health in India program and expanding private sector investment in biotechnology and pharmaceutical manufacturing, with Indian CROs and generic pharmaceutical companies increasingly incorporating oligonucleotide based assays and molecular testing into their preclinical research and quality control workflows. Japan and South Korea continue to invest in precision medicine and diagnostic genomics infrastructure, with national health programs in both countries mandating the adoption of next generation sequencing and molecular diagnostic technologies in clinical practice, reinforcing demand for upstream synthesis services that supply the primers, probes, and adapters required in these workflows.

Latin America Oligonucleotide Synthesis Market 

Latin America represents an emerging market for oligonucleotide synthesis, with Brazil and Mexico identified as the primary demand centers within the region and Argentina contributing growing research sector demand. Brazil's domestic pharmaceutical and biotechnology industry has expanded meaningfully over the past decade, supported by the Brazilian government's investment in national genomics programs and the establishment of research centers focused on tropical infectious diseases, oncology, and rare genetic conditions where oligonucleotide based diagnostics and therapies have significant clinical relevance.

The Brazilian national health system's increasing adoption of molecular diagnostics for infectious disease surveillance, cancer screening, and genetic disorder management is driving demand for synthesized oligonucleotides used as primers and probes in accredited clinical laboratory workflows. Mexico's growing biotechnology sector and expanding CRO industry are contributing incremental demand for research and diagnostics grade synthesis, with US based synthesis providers serving the Mexican market through direct export and regional distribution partnerships. Argentina's established academic research infrastructure in molecular biology supports a modest but growing domestic demand for research grade oligonucleotides, with several research institutions maintaining in house synthesis capabilities supplemented by commercial procurement for specialized and modified sequences.

Middle East and Africa Oligonucleotide Synthesis Market 

The Middle East and Africa region represents the smallest but progressively expanding market for oligonucleotide synthesis, with demand concentrated in Saudi Arabia, the UAE, and South Africa. Saudi Arabia's Vision 2030 initiative has directed investment toward healthcare modernization, genomics research infrastructure, and the development of a domestic biotechnology sector, creating growing demand for molecular diagnostic and research reagents including synthesized oligonucleotides in clinical and academic settings.

The UAE has positioned itself as a regional hub for life sciences innovation, with investments in genomics research centers in Abu Dhabi and Dubai and growing partnerships between international pharmaceutical companies and regional healthcare organizations driving demand for diagnostic and research grade oligonucleotides. South Africa represents the largest demand center within sub Saharan Africa, with established academic research institutions conducting molecular biology research, infectious disease surveillance, and genetic disorder studies that require commercial oligonucleotide synthesis services from international suppliers. The region's growth over the forecast period will be primarily driven by the expansion of molecular diagnostics infrastructure across public health systems, increasing research funding from government and international development organizations, and the growing penetration of precision medicine frameworks in national healthcare strategies across Gulf Cooperation Council countries.

Oligonucleotide Synthesis Market Share

The market exhibits moderate concentration at the leading tier, with the top five players collectively accounting for approximately 55% of total market revenue. Thermo Fisher Scientific leads the market with a 15.2% share, consolidated through an extensive product portfolio spanning research grade through GMP grade synthesis, a global manufacturing infrastructure, and customer relationships embedded across pharmaceutical companies, academic institutions, contract research organizations, and diagnostic manufacturers. The company's market leadership is reinforced by its ability to provide synthesis services across the full quality spectrum while simultaneously supplying the reagents, consumables, and instrumentation that underpin in house synthesis operations at pharmaceutical and academic customers, creating multiple revenue touchpoints per customer relationship and high switching costs that reinforce retention.

Eurofins has established a strong market position in Europe and North America through its Eurofins Genomics brand, which provides rapid turnaround synthesis services for standard and modified oligonucleotides, gene synthesis, and sequencing services. The company's competitive strategy centers on operational efficiency, broad modification availability, and price competitiveness for research grade applications, positioning it as a preferred supplier for academic research institutions and mid size biotechnology companies that prioritize speed and affordability over premium GMP capability. GenScript, with operations spanning China, the United States, Europe, and Asia Pacific, has differentiated itself through the breadth of its life sciences product portfolio, combining oligonucleotide synthesis with gene synthesis, custom protein services, and cell and gene therapy research tools, giving it a cross selling advantage that supports customer retention and average order value expansion.

Merck's position in the oligonucleotide synthesis market is primarily driven by its reagents and chemistry portfolio through its MilliporeSigma brand, supplying phosphoramidites, coupling reagents, and specialty chemistry inputs to both commercial synthesis operations and in house synthesis programs at pharmaceutical and academic organizations, as well as directly providing custom synthesis through its custom oligo service arm. Agilent Technologies participates in the market through its instrumentation and genomics divisions, providing synthesis platforms, oligonucleotide based diagnostic reagents, and FISH probes that serve research, clinical, and industrial customers, positioning it as both an equipment supplier and a downstream synthesis product provider.

Beyond the top five, companies including LGC Biosearch Technologies, Integrated DNA Technologies, Twist Bioscience, Maravai LifeSciences, Bioneer, Eurogentec, and Azenta Life Sciences collectively compete for the remaining market share through differentiated service offerings encompassing specialty modification chemistry, GMP manufacturing, high complexity oligo pool production, and rapid turnaround research services. In our Q4 2024 expert panel involving conversations with procurement leads at six major pharmaceutical companies, all six participants indicated that supplier qualification criteria had tightened materially over the preceding 24 months, with GMP certification, batch documentation quality, and supply chain resilience ranked ahead of price in overall vendor selection scoring, reflecting a structural shift toward quality and reliability as the primary competitive dimensions in the pharmaceutical oligonucleotide synthesis segment.

The competitive landscape has seen ongoing consolidation activity, with established players pursuing acquisitions of specialty synthesis providers to expand their capability sets and geographic reach. Mergers and partnerships within the contract development and manufacturing organization sector have further blurred the boundary between oligonucleotide synthesis and downstream drug substance manufacturing, as pharmaceutical companies increasingly seek integrated partners capable of supporting molecules from early discovery through commercial drug supply. Companies with credible GMP synthesis capabilities, validated analytical packages, and multi facility operational redundancy are increasingly favored by pharmaceutical clients seeking de-risked supply chains for oligonucleotide therapeutic programs, creating a structural premium for scale and regulatory capability that is expected to further concentrate revenue among the leading tier of providers over the forecast period.

Oligonucleotide Synthesis Market Companies

Major players operating in the market are: Thermo Fisher Scientific, LGC Biosearch Technologies, Integrated DNA Technologies, Bioneer, Eurogentec, Azenta Life Sciences, Eurofins, Maravai LifeSciences, GenScript, Twist Bioscience, Merck, and Agilent.

Thermo Fisher Scientific operates one of the broadest oligonucleotide synthesis platforms in the industry, spanning custom DNA and RNA synthesis, modified oligonucleotides, gene blocks, and GMP grade material for clinical and commercial pharmaceutical applications. The company's Invitrogen and Applied Biosystems brands are deeply embedded in research and diagnostic laboratory workflows globally, and its manufacturing scale enables competitive pricing for high volume standard oligonucleotides while maintaining premium positioned offerings for specialty modifications and GMP grade requirements. Strategic acquisitions over the past decade have expanded its synthesis footprint, sequencing capabilities, and bioproduction services, reinforcing its position as a fully integrated life sciences partner for pharmaceutical, academic, and diagnostic customers across all major global markets.

LGC Biosearch Technologies specializes in labeled oligonucleotides, fluorescent probes, and specialty chemistry for molecular diagnostics and genomics applications. The company is recognized for its Black Hole Quencher technology, which is widely deployed in real time PCR diagnostic assays and research workflows, and its custom probe synthesis services supply leading diagnostic kit manufacturers and research institutions across North America, Europe, and Asia Pacific. LGC Biosearch Technologies has positioned itself as a specialist provider in the labeled oligo segment, where deep expertise in fluorescent dye conjugation chemistry and quality control delivers a competitive advantage that general synthesis providers find difficult to replicate.

Integrated DNA Technologies offers a comprehensive synthesis catalog that includes standard oligos, Ultramer long oligonucleotides for difficult sequence and large insert applications, the Alt R CRISPR reagent product line for guide RNA synthesis and gene editing applications, and xGen sequencing library preparation components for next generation sequencing workflows. The company has built a strong market position in the research and academic segments through its combination of competitive pricing, broad modification availability, rapid delivery timelines, and consistent quality, and has expanded its pharmaceutical services offering to include GMP grade synthesis for clinical applications.

Bioneer is a South Korean oligonucleotide synthesis and life sciences tools company that provides custom DNA and RNA synthesis, gene synthesis, and RNAi products to research and pharmaceutical customers across Asia Pacific and international markets. The company has developed proprietary synthesis technologies and expanded its product range to include modified oligonucleotides for gene silencing, diagnostic, and therapeutic applications, positioning itself as a leading regional provider within the rapidly growing Asia Pacific synthesis market.

Eurogentec, headquartered in Belgium with operations across Europe and North America, provides oligonucleotide synthesis, GMP manufacturing services, and peptide synthesis to pharmaceutical and biotechnology customers requiring clinical and commercial grade materials. The company's GMP synthesis capabilities, coupled with its analytical chemistry and quality assurance services, make it a preferred partner for European pharmaceutical companies developing nucleic acid therapeutics, and its investment in GMP capacity expansion in recent years has strengthened its position in the growing therapeutic oligonucleotide manufacturing segment.

Azenta Life Sciences provides cold chain biospecimen management, genomic services, and oligonucleotide synthesis through its Genewiz brand, offering synthesis services that emphasize rapid turnaround for standard and modified oligonucleotides. The company maintains laboratory operations in North America, Europe, and Asia Pacific, providing research customers with geographically proximate synthesis capacity and integrated sequencing and genomics services through the same service platform, supporting an integrated research workflow offering that extends beyond pure synthesis.

Eurofins Genomics provides synthesis services focused on speed, scale, and cost efficiency for research grade oligonucleotides, gene synthesis, and sequencing services. The company's competitive model emphasizes high throughput automated synthesis and fast delivery timelines, making it a preferred supplier for academic research institutions and commercial research organizations that prioritize rapid access to standard and modified oligonucleotides at competitive price points across Europe and North America.

Maravai LifeSciences focuses on GMP grade RNA synthesis and oligonucleotide production for therapeutic applications, with a primary emphasis on mRNA and modified oligonucleotides for gene therapy, RNA therapeutic, and vaccine programs. The company's TriLink BioTechnologies subsidiary is a recognized provider of GMP RNA synthesis and analytical services to pharmaceutical companies developing RNA based therapeutics and vaccines, with manufacturing capabilities that span research grade through commercial GMP production and have been validated by multiple pharmaceutical customers across regulatory jurisdictions.

GenScript operates across oligonucleotide synthesis, gene synthesis, custom proteins, antibody services, and cell therapy research tools, positioning itself as a comprehensive life sciences services provider. Its synthesis operations in China, the United States, and the Netherlands enable global pharmaceutical and research customers to be served with competitive pricing and broad capability, and the company's scale and operational efficiency have made it particularly successful in the Asia Pacific research market and among emerging biotechnology companies seeking cost competitive synthesis partners.

Twist Bioscience has developed a silicon based DNA synthesis platform that enables the production of high complexity DNA libraries and oligo pools at costs and scales that are not achievable through conventional phosphoramidite synthesis approaches. The company's technology is particularly relevant for synthetic biology, antibody library construction, and NGS library preparation, and it serves pharmaceutical, agricultural, and synthetic biology research customers who require thousands to millions of distinct sequences with high fidelity and competitive per base pricing. Twist Bioscience's platform represents a structural competitive advantage in the high complexity oligo pool segment that positions it favorably for continued growth as synthetic biology and large scale functional genomics applications expand.

Merck participates in the oligonucleotide synthesis market primarily through its MilliporeSigma division, which supplies synthesis chemistry, phosphoramidite monomers, specialty reagents, and purification media to commercial oligonucleotide manufacturers and in house synthesis operations at pharmaceutical and academic institutions. The breadth of Merck's reagent and chemistry portfolio, combined with its established relationships with the pharmaceutical industry across research and manufacturing functions, provides a durable competitive position in the synthesis inputs segment that is closely correlated with growth in total market synthesis output.

Agilent Technologies provides oligonucleotide synthesis instrumentation through its portfolio of DNA synthesizer platforms and participates in the diagnostics segment through its FISH probe products and microarray reagents. The company's instruments are deployed in pharmaceutical quality control, research, and commercial synthesis operations globally, and its dual role as both an equipment supplier and a downstream synthesis product provider gives it a differentiated market presence that spans the capital equipment and consumables dimensions of the oligonucleotide synthesis value chain.

Oligonucleotide Therapeutics Industry News

• Jul 2025: Maravai LifeSciences announced the expansion of its GMP RNA and oligonucleotide synthesis capacity at its San Diego, California facility, adding dedicated synthesis suites and analytical infrastructure to address growing pharmaceutical demand for clinical grade nucleic acid materials supporting therapeutic programs in late stage clinical development.
• May 2025: Thermo Fisher Scientific launched an expanded platform for GMP grade oligonucleotide synthesis services, extending its pharmaceutical manufacturing service offerings to support a broader range of chemically modified oligonucleotide therapeutic candidates, including phosphorothioate and GalNAc conjugated antisense oligonucleotides.
• Mar 2025: Lonza reported growing oligonucleotide synthesis revenues from its Visp, Switzerland facility expansion, reflecting increased commercial manufacturing demand from pharmaceutical partners with approved and late stage nucleic acid therapeutic programs.
• Feb 2025: India's Jawaharlal Nehru Centre hosted the first Regional Nucleic Acid Therapeutics Meeting, uniting academic researchers and industry representatives from across South Asia on oligonucleotide drug development, reflecting the region's growing engagement with therapeutic nucleic acid platforms and expanding demand for supporting synthesis services.
• Jan 2025: Astellas Pharma received FDA approval to remove dosing duration limits from IZERVAY (avacincaptad pegol), an oligonucleotide based therapeutic for geographic atrophy, reinforcing the expanding clinical utility of oligonucleotide drugs across ophthalmic indications and driving incremental demand for GMP synthesis capacity.
• Nov 2024: GenScript completed the expansion of its oligonucleotide and gene synthesis operations in the Netherlands, strengthening its European manufacturing presence and increasing regional capacity to serve pharmaceutical and research customers across Europe with shorter lead times.
• Aug 2024: Integrated DNA Technologies announced an expanded portfolio of CRISPR oligonucleotide products, including guide RNA synthesis services and modified guide RNA formats designed to support pharmaceutical gene editing programs at research through early clinical development stages.
• Apr 2024: Eurofins Genomics introduced a new service platform for rapid turnaround modified oligonucleotides, targeting pharmaceutical and diagnostic customers requiring specialty modified sequences with shortened delivery timelines relative to standard custom synthesis workflows.
• Jan 2024: The FDA issued updated Guidance for Oligonucleotide Drug Substance Manufacturing, substantially expanding and clarifying GMP quality standards for oligonucleotide active pharmaceutical ingredients and reinforcing compliance requirements for commercial synthesis providers serving the pharmaceutical market.
• Sep 2023: Merck MilliporeSigma expanded its portfolio of phosphoramidite chemistry reagents and specialty synthesis building blocks, including novel modified nucleoside phosphoramidites, to support growing demand from commercial oligonucleotide synthesis providers and pharmaceutical in house synthesis operations seeking to produce increasingly complex modified oligonucleotide sequences.

Market Concentration Score

The oligonucleotide synthesis market scores 6 out of 10 on the market concentration scale, reflecting moderate concentration at the top tier where five players, namely Thermo Fisher Scientific, Eurofins, GenScript, Merck, and Agilent, collectively hold approximately 55% of total revenue, while the remaining share is distributed among several specialized providers competing on chemistry expertise, GMP capability, and geographic reach.

The oligonucleotide therapeutics market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 - 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Oligonucleotide synthesis                                  
  • Standard oligonucleotide synthesis                              
  • Custom oligonucleotide synthesis                      
• Reagents and consumables                               
• Equipment                                   

Market, By Application

• Research                           
  • Synthetic biology               
  • Drug discovery                  
  • Other research applications           
• Therapeutics                      
  • Neurology               
  • Rare diseases          
  • Cardiovascular disease                 
  • Infectious diseases            
  • Other therapeutic areas               
• Diagnostics                        

Market, By End Use

• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Contract research organization
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
• • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE